Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps  Latest publication
Bis4
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/05/2021
Bis3
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/05/2021
Procyanidin B2
Potential treatment - theoretical effect Natural product Antiviral Mar/10/2021
Eicosapentaenoic acid
Potential treatment - pre-clinical evidence Natural product Antiviral Mar/04/2021
Calpain inhibitor II
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Mar/01/2021
Linolenic acid
Potential treatment - pre-clinical evidence Natural product Antiviral Mar/04/2021
1,3-Dicaffeoylquinic acid
Potential treatment - theoretical effect Natural product Antiviral Feb/15/2021
Levan N
Potential treatment - theoretical effect Natural product Antiviral Feb/15/2021
C2 (IgG)
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/15/2021
2-Bromo-3-fluoro-N-[(1-methyl-1H-indol-3-yl)sulfonyl]benzamide
Potential treatment - theoretical effect Experimental Antiviral Feb/20/2021
Hydroxyitraconazole
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/05/2021
VS10
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021
2-((3,5-dichlorophenyl)amino)-5-hydroxyquinazolin-4 (3H)-one
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021
mAb 2-36
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/08/2021
1212C2
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/24/2021
Progesterone
Potential treatment - clinical evidence Used to treat other disease Antiviral Feb/11/2021
Rac5c
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/04/2021
C1632
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/22/2021
CIGB-325
Potential treatment - clinical evidence Experimental Antiviral Dec/11/2020